Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322656 | 0.83 | F10 (0.55) | F10DPP4CYP3A4TSHRTDP1 | |
| SCHEMBL6560264 | 0.76 | DPP4 (0.60) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL4480343 | 0.76 | DPP4 (0.60) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL6560281 | 0.76 | DPP4 (0.60) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL4480365 | 0.76 | DPP4 (0.60) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL4490580 | 0.76 | DPP4 (0.60) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL4495195 | 0.76 | DPP4 (0.60) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL6560280 | 0.76 | DPP4 (0.60) | DPP4CYP3A4TSHRTDP1MAPT | |
| SCHEMBL5227429 | 0.72 | DPP4 (0.49) | F10DPP4CYP3A4TSHRTDP1 | |
| SCHEMBL24324200 | 0.72 | DPP4 (0.55) | F10DPP4CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | F10 1781/4885DPP4 532/4885CYP3A4 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.